published meta-analysis   sensitivity analysis   studies

hydroxychloroquine plus macrolides in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsProPAC-COVID, 2021 0.08 [0.00; 8.65] 0.08[0.00; 8.65]ProPAC-COVID, 202110%117NAnot evaluable ICU admissiondetailed resultsProPAC-COVID, 2021 1.24 [0.26; 5.80] 1.24[0.26; 5.80]ProPAC-COVID, 202110%117NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-04-19 22:36 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 559,889 - roots T: 290